HopeStage
Back to all studies
TerminatedNCT03841773

A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSD

Researchers are comparing TNX-102 SL and placebo to find out how the approaches affect post-traumatic stress symptoms in people with PTSD.

Medication studyAges 18–75United States
The study in practice

Understand this study

What is this study about?

Researchers are comparing TNX-102 SL and placebo to find out how the approaches affect post-traumatic stress symptoms in people with PTSD.

Who could participate?

This study is for people with PTSD. Listed age limits: 18 years to 75 years. Other eligibility criteria apply.

Listed locations
Phoenix and 29 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: March 7, 2019
Recruitment status
Terminated
Enrollment listed in the registry
192
Sponsor
Tonix Pharmaceuticals, Inc.
Sponsor type
Other organization
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States
Age range
From 18 Years to 75 Years
Official registry ID
NCT03841773
Official title
Show the full official title

A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSD Taken Daily at Bedtime (Protocol No. TNX-CY-P302)

Recruitment & locations

Terminated

Phoenix · Little Rock · Rogers

27 more locations
  • Beverly Hills
  • Oceanside
  • Orange
  • Panorama City
  • Riverside
  • San Diego
  • Temecula
  • Colorado Springs
  • Norwich
  • Washington D.C.
  • Jacksonville
  • North Miami
  • Orlando
  • Tampa
  • Alpharetta
  • Lincolnwood
  • Boston
  • New Bedford
  • Flowood
  • St Louis
  • Las Vegas
  • Oklahoma City
  • Portland
  • Salem
  • Memphis
  • Austin
  • Dallas

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What is this study about?

Researchers are comparing TNX-102 SL and placebo to find out how the approaches affect post-traumatic stress symptoms in people with PTSD.

Who is behind this study?

The study sponsor is Tonix Pharmaceuticals, Inc.

Does this study involve medication?

Yes. The study involves medication, including TNX-102 SL and Placebo SL Tablets.

Who can participate?

This study is for people with PTSD. Listed age limits: 18 years to 75 years. Other eligibility criteria apply.

Is this study still recruiting?

The registry lists this study as terminated.

Want to explore more studies?

Explore studies